The benefits of caffeine consumption in patients with Alzheimer's disease

Abstract

The aim of this study is to evaluate the potential benefits of caffeine consumption in patients with Alzheimer's Disease (AD) through an integrative review of the literature. The research was conducted in August 2024, using the PubMed and Lilacs databases, and selecting articles published in the last five years. A total of 10 articles were found, of which 5 were used after applying the inclusion and exclusion criteria. The analyzed studies suggest that coffee and caffeine consumption may be associated with neuroprotective effects, possibly slowing cognitive decline related to AD. However, the findings are varied and often inconclusive due to the lack of rigorous randomized clinical trials and heterogeneity in outcomes. The review suggests that bioactive components of coffee, beyond caffeine, may contribute to potential therapeutic benefits, highlighting the need for further research to clarify these effects. It is concluded that, while there are promising indications regarding the benefits of coffee and caffeine, additional studies with robust methodologies are needed to determine the efficacy and safety of these substances as preventive strategies in AD.